INVION

Invion is a clinical-stage life-science company that is leading the global research and development of the Photosoft technology for the treatment of a range of cancers, atherosclerosis and infectious diseases. Invion holds the exclusive Australia and New Zealand license rights and exclusive distribution rights to Asia Pacific excluding China (other than Hong Kong, which is included in the Territory), Macau, Taiwan and Japan to the Photosoft technology for all cancer indications. It also holds the exclusive rights to the technology in Asia Pacific (excluding Greater China) for atherosclerosis and infectious diseases, and subsequently acquired the rights to the United States for infectious diseases. Research and clinical cancer trials in ANZ are funded by the technology licensor, RMW Cho Group Limited... Invion is developing the next-generation Photodynamic Therapy called Photosoft™ for the treatment of cancers and infectious diseases.

Also known as: Invion Limited

Primary location: South Melbourne Australia